House begins campaign to publicize and politicize drug pricing

Requests for pricing and cost information sent Monday by the House Oversight and Reform Committee to a dozen biopharma companies mark the start of what is certain to be a sustained campaign by House Democrats to publicize and politicize drug pricing.

“The letters are the first step in the Committee’s comprehensive review of pricing practices,” the Oversight Committee announced in a press release. ...